Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

176.57 -3.50 (-1.94%)
Streaming Delayed Price Updated: 9:52 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG... 
Via Benzinga
You Won't Believe the Risk This Healthcare Company Faces
It's older than the dinosaurs. 
Via The Motley Fool
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
Where Charles River Stands With Analysts
Charles River (NYSE:CRL) has observed the following analyst ... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
Thursday morning saw 166 companies set new 52-week highs. Interesting Highlights: The largest company by market cap to hit a new 52-week high was Microsoft (NASDAQ:... 
Via Benzinga
Illumina Stock Earns Membership In Elite Club
Illumina saw its IBD SmartSelect Composite Rating rise to 97 Tuesday, up from 93 the day before. 
Via Investor's Business Daily
Medpace Stock Shows Rising Price Performance With Jump To 83 RS Rating
Medpace sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
How Does Charles River's Debt Look?
Shares of Charles River (NYSE:CRL) rose by 27.14% in the past three months. Before having a look at the importance of debt, let us look at how much debt Charles River has.... 
Via Benzinga
Charles River Laboratories International, inc (CRL) Q2 2021 Earnings Call Transcript
CRL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Recap: Charles River Q2 Earnings
Shares of Charles River (NYSE:CRL) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 65.19% year over year to $2.61,... 
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
10 Top-Ranked Stocks Powering S&P 500 ETF
Though most stocks in the fund’s portfolio have been in the deeper green so far this year, here are 10 stocks that led the rally. 
Via Talk Markets
Topics Stocks
Charles River Laboratories Completes Acquisition of Vigene Biosciences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River's Jim Foster Beat The Trauma Of Being CEO
Think taking over the family business is easy? Charles River CEO Jim Foster might beg to differ. He's shown that being CEO comes with trauma. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
This morning 94 companies set new 52-week highs. Things to Consider: NVIDIA (NASDAQ:NVDA) was the largest firm by market cap to set a new 52-week high. Deswell Industries... 
Via Benzinga
Bio-Techne Stock Shows Rising Strength As The Small Cap Nears Billion-Dollar Run Rate
Bio-Techne's revenue grew 25% last quarter. Revenue growth has risen the past four quarters as it nears entry in the billion-dollar a year run-rate club. 
Via Investor's Business Daily
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
From Charles River Laboratories International, Inc.
Via Business Wire
Agilent Technologies Stock Shows Rising Relative Strength
The Relative Strength (RS) Rating for Agilent Technologies stock moved up into a new percentile Friday, as it got a lift from 67 to 71. 
Via Investor's Business Daily
Charles River Laboratories to Participate in June Investor Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Host Virtual Investor Day
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Acquires Viral Vector Player For $350M
Contract researcher Charles River Laboratories International Inc (NYSE: CRL) will dole out $292.5 million for gene therapy CDMO Vigene Biosciences with the... 
Via Benzinga
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Labs Joins Elite List Of Stocks With 95-Plus Composite Rating
Charles River Labs' Accumulation/Distribution Rating of A, on an A+ to E scale, shows heavy buying by institutional investors over the last 13 weeks. 
Via Investor's Business Daily
Charles River Laboratories International Inc (CRL) Q1 2021 Earnings Call Transcript
CRL earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Charles River: Q1 Earnings Insights
Shares of Charles River (NYSE:CRL) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 37.50% year over... 
Via Benzinga
Charles River Laboratories Announces First-Quarter 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Three Medical Stocks To Watch, Including One With A Potential Breakout
Two have recent breakouts under their belts while a third is eyeing a fresh buy point. 
Via Investor's Business Daily
Medpace Holdings Stock At The Top Of Buy Range With Earnings On Deck
Medpace is in a potential buy range with its next earnings report scheduled for Apr. 26. The medical stock is about 3% above a 177.22 buy point from a second-stage... Read More 
Via Investor's Business Daily
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.